Please login to the form below

Not currently logged in
Email:
Password:

Veltassa

This page shows the latest Veltassa news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Vifor’s Veltassa (patiromer) gained US approval in 2015 and in Europe in 2017. ... Denmark. This has given Vifor a head start overall, but Veltassa sales remain modest: it chalked up revenues of 36.8m in the first six months of 2018.

Latest news

  • Real-world data finds patients feel better on Entresto, says Novartis Real-world data finds patients feel better on Entresto, says Novartis

    Lokelma (sodium zirconium cyclosilicate or ZS-9) and Vifor Pharma’s Veltassa (patiromer) which “will be a particularly valuable addition to the clinic if efficacy can be confirmed in clinical trials”.

  • AZ gets US approval for Veltassa rival Lokelma AZ gets US approval for Veltassa rival Lokelma

    But GlobalData predicts Veltassa has the edge due to positive data in chronic hyperkalaemia. ... That left AZ playing catch-up in the market with Vifor’s Veltassa (patiromer), which was approved in the US in 2015 and got a European green light last

  • AZ finally gets EU nod for Veltassa rival Lokelma AZ finally gets EU nod for Veltassa rival Lokelma

    challenge Vifor Pharma’s Veltassa (patiromer) which was approved in the EU last year and has been sold in the US since 2015. ... For its part, Vifor has said securing payer coverage for Veltassa in the US has been a little slow, but is gaining momentum

  • Vifor wins European approval for Veltassa Vifor wins European approval for Veltassa

    The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the

  • FDA turns down AZ's ZS-9 once again on manufacturing issues FDA turns down AZ's ZS-9 once again on manufacturing issues

    On the plus side for AZ it seems that safety is not causing a concern for the regulator - something that resulted in rival drug Veltassa (patiromer) from Relypsa - now part of ... Veltassa was launched in early 2016 - becoming the first new drug for

More from news
Approximately 3 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    The Vifor division, which focuses on treatments for iron deficiency, has gained a fully integrated US operation prior to the spin-out, and a complementary product in Veltassa, a potassium binder ... Veltassa was approved in late 2015 and Relypsa achieved

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics